How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

935 results for

Medication Causes of Dyspepsia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication

Gastroenterol Hepatol 2012;9:132–9. 4. Agoritsas T , Merglen A, Shah ND, et al. Adjusted analyses in stud- ies addressing therapy and harm: Users’ guides to the medical lit- erature. JAMA 2017;317:748–759. 5. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clin- ical guideline: Management of Dyspepsia. Am J Gastroenterol 2017;112:988–1013. 6. Hong Kong Council on Smoking and Health. Government released the 2012 Hong Kong Smoking Prevalence. (Accessed March 1, 2018). 7. Tredaniel J, Buffetta P, Buiatti (...) E, et al. Tobacco smoke and gastric cancer: Review and meta-analysis. Int J Cancer 1997;72:565–73. 8. Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: Result from a meta-analysis of cohort studies. Eur J Cancer 2009;45:2867–73. 9. W ang B. Dyspepsia: What you think it is, is different than what doc - tors thinks it is [Chinese]. Medical community Gastroenterology Channel. (Accessed May 1, 2018). 10. Lipsitch M, Tchetgen Tchetgen E, et al. Negative controls: A tool

2019 Canadian Association of Gastroenterology

82. Robot-assisted surgery in thoracic and visceral indications

IN THORACIC AND VISCERAL INDICATIONS Project ID: OTCA14 Robot-assisted surgery for thoracic and visceral surgery Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 31.01.19 First draft. V1.1 27.02.19 Input from co-author has been processed. V1.2 29.03.19 Input from dedicated reviewers has been processed. V1.3 30.04.19 Input from external experts and manufacturer(s) has been processed. V1.4 06.05.19 Input from medical editing has been (...) MD Mean difference Ø Mean M Median MeSH Medical Subject Headings mg milligram Robot-assisted surgery for thoracic and visceral surgery Version 1.4, 06.05.2019 EUnetHTA Joint Action 3 WP4 7 ml milliliter n Number n/a Not applicable NCCN National Comprehensive Cancer Network NIH National Institute for Health NR Not reported NRS Numeric Rating Scale ns Not significant NSCLC Non-small cell lung Cancer p Power PFDI Pelvic Floor Distress Inventory PFIQ Pelvic Floor Impact Questionnaire PISQ Pelvic

2019 EUnetHTA

83. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents

or non-existent, suggest that approximately 80% of people dying from cancer experience moderate or severe pain lasting on average for 90 days (5). Thus, cancer pain is a major cause of unnecessary suffering.15 1. I NTRODUCTION Everyone has a right to the enjoyment of the highest attainable standard of physical and mental health, and states have an obligation to take steps towards “the creation of conditions which would assure to all medical service and medical attention in the event of sickness” (6 (...) interests were managed 104 ANNEX 5: OPIOID ANALGESICS AND INTERNATIONAL CONVENTIONS 105 United Nations drug conventions and their governance system 105 The Single Convention on Narcotic Drugs and opioid analgesics 106 Drug misuse versus patient need 107 Competent national authorities under the international drug control treaties 108 The Convention’s requirements for national estimates of medical need for opioids 108 The importance of reliable estimates 109 Domestic manufacture of strong opioid

2019 World Health Organisation Guidelines

84. AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm

, but these reductions came at the cost of requiring more antihypertensive medications and produced a significantly higher number of serious adverse events (SAEs). In particular, a greater likelihood of decline in renal function was observed in the intensive arm of ACCORD-BP ( ). A meta-analysis of antihypertensive therapy in patients with T2D or impaired fasting glucose demonstrated similar findings. Systolic BP ≤135 mm Hg was associated with decreased nephropathy and a significant reduction in all-cause mortality (...) patient and cannot replace the judgment of a clinician. From the 1 Chair, Professor, Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 2 Beth Israel Deaconess Medical Center, Department of Medicine and Harvard Medical School, Boston, Massachusetts 3 Division of Endocrinology Kaiser Permanente of Georgia and the Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia 4 Director, Ochsner

Full Text available with Trip Pro

2019 American Association of Clinical Endocrinologists

85. Paediatric Urology

, H.N., et al. Reduced bacterial colonisation of the glans penis after male circumcision in children--a prospective study. J Pediatr Urol, 2013. 9: 1137. 30. Larke, N.L., et al. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control, 2011. 22: 1097. 31. Thompson, H.C., et al. Report of the ad hoc task force on circumcision. Pediatrics, 1975. 56: 610. 32. American Academy of Pediatrics: Report of the Task Force on Circumcision. Pediatrics, 1989. 84: 388. 33 (...) in Henoch-Schonlein purpura. Eur Radiol, 2001. 11: 2267. 130. Diamond, D.A., et al. Neonatal scrotal haematoma: mimicker of neonatal testicular torsion. BJU Int, 2003. 91: 675. 131. Ha, T.S., et al. Scrotal involvement in childhood Henoch-Schonlein purpura. Acta Paediatr, 2007. 96: 552. 132. Hara, Y., et al. Acute scrotum caused by Henoch-Schonlein purpura. Int J Urol, 2004. 11: 578. 133. Klin, B., et al. Acute idiopathic scrotal edema in children--revisited. J Pediatr Surg, 2002. 37: 1200. 134. Krause

2019 European Association of Urology

86. Male Sexual Dysfunction

dysfunction. J Sex Med, 2010. 7: 445. 27. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA, 1993. 270: 83. 28. Feldman, H.A., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol, 1994. 151: 54. 29. Fisher, W.A., et al. Erectile dysfunction (ED) is a shared sexual concern of couples I: couple conceptions of ED. J Sex Med, 2009. 6: 2746. 30. Salonia, A., et al. Is erectile dysfunction a reliable proxy (...) . part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 2014. 65: 124. 98. Maggi, M., et al. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med, 2013. 10: 661. 99. Laumann, E.O., et al. The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int J Impot Res, 1999. 11 Suppl 1: S60. 100. Miner, M., et al. Cardiometabolic risk

2019 European Association of Urology

87. Management of Non-neurogenic Male LUTS

: 563. 16. Ficarra, V., et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep, 2014. 15: 463. 17. He, Q., et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis, 2016. 19: 7. 18. Drake, M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn, 2014. 33: 622. 19 (...) : 827. 77. Mochtar, C.A., et al. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol, 2006. 175: 213. 78. Jorgensen, J.B., et al. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br J Urol, 1992. 69: 265. 79. Kranse, R., et al. Causes for variability in repeated pressure-flow measurements. Urology, 2003. 61: 930. 80. Reynard, J.M., et al. The ICS-’BPH’ Study

2019 European Association of Urology

88. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

and obesity, counseling and caloric restriction are recommended for achieving and maintaining weight loss. 5. Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per week of vigorous-intensity physical activity. 6. For adults with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed (...) levels (=190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and those determined to be at sufficient ASCVD risk after a clinician–patient risk discussion. 10. Nonpharmacological interventions are recommended for all adults with elevated blood pressure or hypertension. For those requiring pharmacological therapy, the target blood pressure should generally be $200 billion annually in healthcare services, medications, and lost productivity. Much of this is attributable

2019 American Heart Association

89. Primary Prevention of Cardiovascular Disease

with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. 7. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit. 8. Aspirin should be used infrequently (...) requiring pharmacological therapy, the target blood pressure should generally be $200 billion annually in healthcare services, medications, and lost productivity. Much of this is attributable to suboptimal implementation of prevention strategies and uncontrolled ASCVD risk factors in many adults (S1-2). Most Americans who have had a myocardial infarction (MI) had unfavorable levels of at least 1 cardiovascular risk factor before their ASCVD event (S1-4). In 2010, the AHA defined a new model of “ideal

2019 American College of Cardiology

90. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA/SUFU Guideline

be diagnosed with overactive bladder (OAB). 27 Additionally, a caregiver or partner may perceive these symptoms as bothersome and lead the patient to seek care. It is common for patients to have suffered with their symptoms for an extended time before seeking medical advice. Differentiation. OAB symptoms (frequency, urgency and urgency incontinence) may occur only at night, causing a single symptom of nocturia. The differential of nocturia includes nocturnal polyuria (the production of greater than 20 (...) to be continent or have a desire for symptom improvement. In patients with cognitive deficits, this desire may not be present and family and/or caregivers may have difficulty understanding that simply giving a medication will not correct the problem. The other common situation associated with OAB is severely reduced mobility. Causes can range from dementia, severe arthritis, severe obesity, hemiparesis/plegia, and lower extremity amputations. In these situations, despite receiving an urge to urinate

2019 American Urological Association

91. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease

: TNF; 5-ASA; Guidance; Mucosal Healing Crohn’s disease (CD) is a lifelong illness with substantial mor- bidity and mortality. Studies have shown that up to one-third of patients require hospitalization within the first year after diagnosis and more than half within 5 years. 1 In addition to in- creased risk of mortality from digestive conditions, CD is also associated with a significantly increased risk of all-cause mortal - ity compared with the general population (standardized mor- tality ratio (...) , 1.45; 95% confidence interval [CI], 1.34–1.58). 2 Furthermore, health-related quality of life (HRQoL) is signifi - cantly lower among patients with CD compared with normal populations because of the impact of CD on physical, emo- tional, and social well-being. 3 The cause of CD is not well-defined, which makes it chal - lenging to develop specific targeted treatments, but a number of treatments have demonstrated efficacy in CD. In the last decade, treatment paradigms have changed, recognizing

2019 Canadian Association of Gastroenterology

92. Oesophageal manometry and oesophageal reflux monitoring

for oesophageal manometry for symptoms of dysphagia, regurgitation or chest pain to rule out structural and mucosal causes for their symptoms including eosinophilic oesophagitis. Endoscopy also allows assessment of abnormalities (eg, oesophageal diverticula, pharyngeal pouch, varices, etc), which potentially increase the risk of insertion of a catheter into the oesophagus. Any medication known to affect oesophageal motor function should be stopped for 48 hours prior to the test if possible (eg, nitrates (...) or persistent gastro-oesophageal reflux symptoms following antireflux surgery should undergo reflux monitoring by pH/impedance, rather than pH moni- toring alone, as this can objectively confirm or reject persistent gastro-oesophageal reflux and exclude other causes for symp- toms such as supragastric belching. GRADE evidence: Low Strength recommendation: Conditional/weak 3. Wireless oesophageal pH monitoring Technical aspects of wireless pH monitoring 3.1 Wireless pH monitoring should be undertaken

2019 British Society of Gastroenterology

93. Management of Atopic Eczema

Management of Atopic Eczema Management of Atopic Eczema Published by: Malaysian Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 Federal Government Administrative Centre 62590 Putrajaya, Malaysia Copyright The copyright owner of this publication is MaHTAS. Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to MaHTAS is included and the content (...) Atopic Dermatitis (Hanifin and Rajka Criteria) Appendix 4 Investigator’s Global Assessment (IGA) 44 Appendix 5 Dermatology Life Quality Index 45 Appendix 6 Children Dernatology Life Quality Index 46 Appendix 7 Topical Corticosteroids Class & Potency 47 (UK Classification) Management of Atopic Eczema TABLE OF CONTENTS No. Title Page Appendix 8 Fingertip Unit 48 Appendix 9 Six Steps of Wet Wrap Therapy 49 Appendix 10 Written Eczema Action Plan 50 Appendix 11 Recommended Medication Dosing, 51 Side

2019 Ministry of Health, Malaysia

94. Taking a hard look at the evidence: Phosphodiesterase-5-inhibitors in erectile dysfunction

Taking a hard look at the evidence: Phosphodiesterase-5-inhibitors in erectile dysfunction Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) % versus ~30% for placebo. For every 3 men given a PDE5 inhibitor compared to placebo, an additional 1 will have “improved erections”. Evidence: • All results statistically significant unless indicated. o Systematic review, 130 randomized controlled trials (RCTs) of most PDE5 inhibitors (sildenafil, vardenafil, tadalafil, mirodenafil, udenafil), over 30,000 patients with erectile dysfunction of any cause. 1,2 After ~12 weeks: ? Proportion of successful sexual intercourse attempts (erection sufficiently

2019 Tools for Practice

95. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults

as bothersome the patient may be diagnosed with overactive bladder (OAB). 27 Additionally, a caregiver or partner may perceive these symptoms as bothersome and lead the patient to seek care. It is common for patients to have suffered with their symptoms for an extended time before seeking medical advice. Differentiation. OAB symptoms (frequency, urgency and urgency incontinence) may occur only at night, causing a single symptom of nocturia. The differential of nocturia includes nocturnal polyuria (...) mobility, which can complicate treatment. To treat incontinence, optimally the patient must have a desire to be continent or have a desire for symptom improvement. In patients with cognitive deficits, this desire may not be present and family and/or caregivers may have difficulty understanding that simply giving a medication will not correct the problem. The other common situation associated with OAB is severely reduced mobility. Causes can range from dementia, severe arthritis, severe obesity

2019 American Urological Association

96. BSG consensus guidelines on the management of inflammatory bowel disease in adults

0SF, UK 31. University of Glasgow, Glasgow, G12 8QQ, UK 32. Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK 33. University of Birmingham, Birmingham, B15 2TT, UK 34. University College London, London, WC1E 6BT, UK 35. University College London Hospitals NHS Foundation Trust, London, NW1 2PG, UK 36. Brighton and Sussex University Hospitals NHS Trust, Brighton, BN2 5BE, UK 37. Brighton and Sussex Medical School, Brighton, BN1 9PX, UK 38. Royal Wolverhampton NHS (...) manuscript 10 Version accepted by Gut 10 th June 2019 4.7 Stricturing disease 90 4.7.1 Medical therapy for strictures 90 4.7.2 Surgical therapy for strictures 90 4.7.3 Strictureplasty 91 4.7.4 Endoscopic therapy for strictures 92 4.8 Non-perianal fistulising Crohn’s disease and abscesses 93 4.8.1 Intra-abdominal abscesses 93 4.8.2 Medical therapy 93 4.8.3 Enterovaginal and enterovesical fistulae 94 4.8.4 Enteroenteric fistulae 94 4.8.5 Enterocutaneous fistulae 95 4.8.6 Anti-TNF therapy for non-perianal

2019 British Society of Gastroenterology

97. Diagnosis and management of patients at risk of gastric adenocarcinoma

and management of patients at risk of gastric adenocarcinoma Matthew Banks , , David Graham , , Marnix Jansen , Takuji Gotoda , Sergio Coda , Massimiliano di Pietro , , Noriya Uedo , Pradeep Bhandari , D Mark Pritchard , Ernst J Kuipers , Manuel Rodriguez-Justo , Marco R Novelli , Krish Ragunath , Neil Shepherd , Mario Dinis-Ribeiro . Statistics from Altmetric.com Executive summary Gastric adenocarcinoma continues to be a frequent cause of death in the world and is the 16th most common cancer in the UK (...) . The most common stages in the progression to gastric adenocarcinoma are gastric atrophy (GA) and gastric intestinal metaplasia (GIM), which are collectively known as chronic atrophic gastritis (CAG). These conditions are principally caused by Helicobacter pylori infection and less commonly by autoimmune gastritis. The key to having a significant impact on the prognosis of gastric adenocarcinoma and its economic burden is to accurately identify individuals at greatest risk and intervene with recognised

2019 British Society of Gastroenterology

98. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

. The information in this report is intended to help healthcare decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of healthcare services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent (...) reviews to assist public- and private-sector organizations in their efforts to improve the quality of healthcare in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new healthcare technologies and strategies. Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention

2019 Effective Health Care Program (AHRQ)

99. Oral supplementation of iron: evolving best practices

In these settings, a clinician should first ask about adherence. Poor compliance is the leading cause of unsatisfactory responses to iron therapy, 7 likely due to the dyspepsia, constipation, and hard stools that frequently accompany supplementation with ferrous sulfate. A stool softener such as docusate is often prescribed to help with this problem. Absent such issues, a clinician may search for an unrecognized source of bleeding, or perhaps consider the presence of a gastrointestinal comorbidity that impairs (...) -to-head trial examining the efficacy of alternate-day-dosing iron, with and without ascorbic acid. It should be noted these supplementation strategies merely serve to optimize a patient’s pre-existing routes for absorbing iron. Although daily dosing schedules lead to less efficient enteric uptake, they are unlikely to cause iron-refractory iron deficiency anemia, defined as “a failure to respond to treatment at a dose of at least 100 mg of elemental iron per day after four to six weeks of therapy.” 6

2019 Clinical Correlations

100. Sufentanil citrate (Dzuveo) - Pain

2.8.2. Labelling exemptions 79 3. Benefit-risk balance 80 3.1. Therapeutic Context 80 3.1.1. Disease or condition 80 3.1.2. Available therapies and unmet medical need 80 3.1.3. Main clinical studies 80 3.2. Favourable effects 80 3.3. Uncertainties and limitations about favourable effects 81 3.4. Unfavourable effects 81 3.5. Uncertainties and limitations about unfavourable effects 82 3.6. Effects Table 82 3.7. Benefit-risk assessment and discussion 83 3.7.1. Importance of favourable and unfavourable (...) : Sufentanil 30 µg sublingual tablet is indicated for the management of acute moderate to severe pain in adult patients in a medically supervised setting (see section 4.2.). The legal basis for this application refers to: Hybrid application (Article 10(3) of Directive No 2001/83/EC). The application submitted is composed of administrative information, complete quality data, a bioavailability study with the reference medicinal product Sufenta Forte Solution for injection 0.05mg/ml and appropriate non

2018 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>